ADP-A2M4CD8 in HLA-A2+ Subjects With MAGE-A4 Positive Esophageal or Esophagogastric Junction Cancers (SURPASS-2)

Official Title

A Phase 2 Open-Label Clinical Trial of ADP-A2M4CD8 in Subjects With Advanced Esophageal or Esophagogastric Junction Cancers


This study will investigate the efficacy of ADP-A2M4CD8 T-cell therapy in subjects who have the appropriate human leukocyte antigen (HLA) and tumour antigen status and whose esophageal or esophagogastric junction (EGJ) cancer expresses the MAGE-A4 protein.

Trial Description

Primary Outcome:

  • Efficacy: Overall Response Rate (ORR)
Secondary Outcome:
  • Number of subjects with treatment -related adverse events (AEs), including serious adverse events (SAEs) as assessed by Common Terminology Criteria for Adverse Events (CTCAE) version 5.0
  • Efficacy: Best overall response (BOR)
  • Time to response (TTR)
  • Duration of Response (DoR)
  • Progression Free Survival (PFS)
  • Overall Survival (OS)
  • Invitro diagnostic (IVD) assay for screening
  • Time taken to achieve peak expansion of genetically engineered T-cells in PBMCs

View this trial on

Interested in this trial?

Print this page and take it to your doctor to discuss your eligibilty and treatment options. Only your doctor can refer you to a clinical trial.


Canadian Cancer Society

These resources are provided in partnership with the Canadian Cancer Society